---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-003670"
form_type: "8-K"
ticker: "AURA"
cik: "0001501796"
company_name: "Aura Biosciences, Inc."
filed_at: "2023-01-06T23:59:59+00:00"
generated_at: "2026-06-20T18:44:04.821732+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Aura Biosciences updates corporate presentation for J.P. Morgan Healthcare Conference

## Summary
- Attending 41st Annual J.P. Morgan Healthcare Conference starting January 9, 2023 in San Francisco.
- Updated corporate presentation filed as Exhibit 99.1 for investor meetings.
- Forward-looking statements caution about risks including clinical trials and regulatory approvals.
- Company's product candidate belzupacap sarotalocan for choroidal melanoma is highlighted.

## SEC filing metadata
- accession: 0001193125-23-003670
- form_type: 8-K
- ticker: AURA
- cik: 0001501796
- company_name: Aura Biosciences, Inc.
- filed_at: 2023-01-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501796/000119312523003670/0001193125-23-003670-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501796/000119312523003670/d377715d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-003670
- JSON: https://secwatch.observer/filing/0001193125-23-003670.json
- Plain text: https://secwatch.observer/filing/0001193125-23-003670.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.